What are the recommended management strategies for a patient with Ehlers‑Danlos syndrome?

Management of Ehlers-Danlos Syndrome

Medical geneticists must establish the definitive diagnosis and EDS subtype first, because approximately 26% of clinically suspected hypermobile EDS cases harbor alternative genetic conditions requiring entirely different management strategies. 1

Initial Diagnostic Pathway

• Refer all suspected EDS patients to medical genetics immediately for formal classification, as they possess the expertise to distinguish among 13 recognized subtypes and coordinate appropriate molecular testing. 2, 3

• For suspected vascular EDS (Type IV), order urgent COL3A1 gene testing without delay—this is a medical emergency with median survival of 48–51 years and high risk of spontaneous arterial rupture. 2, 1

• Hypermobile EDS (80–90% of cases) has no genetic test available; diagnosis relies exclusively on the 2017 clinical criteria: Beighton score ≥5/9, soft/velvety skin without fragility, and exclusion of alternative diagnoses through genetic testing. 2, 1

Cardiovascular Surveillance (All Subtypes)

• Obtain baseline echocardiogram in every EDS patient to assess aortic root diameter, as dilation occurs in 25–33% of hypermobile and classic types. 2, 1

• Imaging schedule based on aortic dimensions:

  • Every 2–3 years while still growing and aortic root is normal 2
  • Annually if diameter <4.5 cm and growth <0.5 cm/year 2
  • Every 6 months if diameter >4.5 cm or growth ≥0.5 cm/year 2, 1

• For vascular EDS, perform baseline MR angiography from head to pelvis to map the entire arterial tree, then repeat annually for any dilated or dissected segments. 2, 1

Vascular EDS-Specific Management

• Transfer care to vascular surgery and cardiology after genetic diagnosis for coordinated surveillance imaging using only non-invasive modalities (Doppler ultrasound, CT, or MRI). 3, 1

• Avoid all invasive vascular procedures—arterial catheterization, angiography, and surgical interventions carry fatal complication risk; rely exclusively on non-invasive imaging. 3, 1

• Consider celiprolol to reduce vascular morbidity, though it lacks FDA approval in the United States. 1

Hypermobile EDS Multisystem Management

Musculoskeletal

• Prescribe low-resistance exercise and physical therapy as the cornerstone of joint stabilization; avoid high-impact activities that provoke dislocations. 1

• Screen for osteoporosis, scoliosis, and congenital hip dislocation, which are common structural complications. 1

Gastrointestinal (affects up to 98% of hEDS patients)

• Initiate proton pump inhibitors, H2-blockers, or sucralfate for reflux and gastritis. 1

• Use promotility agents for documented delayed gastric emptying. 1

• Do not escalate to invasive nutrition support (feeding tubes, TPN) in pain-predominant presentations, as most hEDS patients have visceral hypersensitivity rather than true dysmotility. 1

• Avoid opioid dependence for chronic abdominal pain, which is particularly problematic in this population. 1

Autonomic Dysfunction

• Measure postural vital signs with active stand test: heart rate increase ≥30 bpm in adults (≥40 bpm in adolescents 12–19 years) within 10 minutes of standing without orthostatic hypotension confirms POTS, which affects 37.5% of hEDS patients. 2, 3

• Refer to neurology or autonomic specialists for tilt-table testing and expanded autonomic function assessment if postural vital signs are positive. 2

Mast Cell Activation Syndrome

• Obtain baseline serum tryptase only if the patient reports episodic multisystem symptoms (≥2 organ systems: flushing, urticaria, wheezing); do not screen routinely in isolated GI symptoms. 2, 1

• Diagnostic threshold for MCAS: tryptase increase of 20% above baseline plus 2 ng/mL during symptomatic flares. 2

Pregnancy Management (Vascular EDS)

• Counsel women with vascular EDS about high maternal mortality risk from uterine and arterial rupture; discuss alternatives to pregnancy. 4

• If pregnancy proceeds, provide joint cardiac-obstetric management with serial echocardiograms throughout gestation. 4

• Reserve cesarean section for aortic root >4.5 cm or prolonged second stage; otherwise, vaginal delivery with epidural anesthesia (after excluding dural ectasia) is preferred. 4

• Retain sutures longer than normal (at least 14 days) and extend antibiotic prophylaxis until removal, as wound dehiscence is common. 4

• Anticipate postpartum hemorrhage and have blood products immediately available. 4

Critical Pitfalls to Avoid

• Never diagnose hypermobile EDS without genetic testing to exclude alternative conditions—more than one-quarter of clinically suspected cases have different underlying genetic disorders requiring distinct management. 1

• Never perform invasive arterial procedures in vascular EDS; fatal complications have been reported with angiography and catheterization. 3, 1

• Do not overlook comorbid POTS, mast cell activation disorder, and chronic urinary retention—screen systematically in all hEDS patients. 1

• Avoid stimulant medications (e.g., methylphenidate) in patients with POTS, as they exacerbate autonomic instability and tachycardia. 2

Multidisciplinary Coordination

• Assemble a core team including medical genetics, cardiology, gastroenterology, physical medicine & rehabilitation, and rheumatology to address the multisystem nature of EDS. 3

• Incorporate clinical psychology or liaison psychiatry, as anxiety, depression, and maladaptive coping are common in chronic dysmotility and hEDS. 2